摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氨基-2,6-二氯-3-硝基吡啶嘧啶 | 2897-43-0

中文名称
4-氨基-2,6-二氯-3-硝基吡啶嘧啶
中文别名
4-氨基-2,6-二氯-3-硝基吡啶;2,6-二氯-4-氨基-3-硝基吡啶;2,6-二氯-3-硝基-4-氨基吡啶
英文名称
2,6-dichloro-3-nitropyridin-4-amine
英文别名
4-amino-2,6-dichloro-3-nitropyridine;2,6-dichloro-3-nitropyridin-4-ylamine;2,6-dichloro-3-nitro-4-aminopyridine;2,6-dichloro-3-nitro-4-pyridinamine;2,6-dichloro-4-amino-5-nitropyridine
4-氨基-2,6-二氯-3-硝基吡啶嘧啶化学式
CAS
2897-43-0
化学式
C5H3Cl2N3O2
mdl
——
分子量
208.004
InChiKey
KJVKGYRFRFXCQQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    148-150°C
  • 沸点:
    426.6±40.0 °C(Predicted)
  • 密度:
    1.723
  • 溶解度:
    易溶于可溶于氯仿、甲醇

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    84.7
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    Xn
  • 安全说明:
    S26
  • 危险类别码:
    R22,R36
  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    -20°C 冰箱,处于惰性气氛中

SDS

SDS:9fbd77939c2eaad610367047d4111fd0
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Amino-2,6-dichloro-3-nitropyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Amino-2,6-dichloro-3-nitropyridine
CAS number: 2897-43-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H3Cl2N3O2
Molecular weight: 208

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

2,6-二-3-硝基吡啶-4-胺可以作为有机合成中间体和医药中间体,主要应用于实验室研发及化工生产过程。

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    参考文献:
    名称:
    NOVEL PHARMACEUTICALS
    摘要:
    本发明涉及公式(I)的免疫应答调节剂,通过对Toll样受体(TLRs)的激动作用具有选择性,其用途,其制备方法,用于其制备的中间体以及含有所述抑制剂的组合物。这些抑制剂在包括治疗传染病(如肝炎(例如HCV,HBV),遗传相关病毒感染和癌症在内的各种治疗领域中具有用途。
    公开号:
    US20070197478A1
  • 作为产物:
    参考文献:
    名称:
    Efficient synthesis of 4-amino-2,6-dichloropyridine and its derivatives
    摘要:
    摘要:开发了一种简便的合成路径,制备了一个重要的中间体4-氨基-2,6-二氯吡啶。以2,6-二氯吡啶为起始原料进行氧化得到吡啶N-氧衍生物,随后进行硝化和还原。随后对产物进行进一步硝化和亲核取代反应,得到全取代的高能吡啶衍生物。大多数合成反应在温和条件下进行。
    DOI:
    10.1515/hc-2016-0132
点击查看最新优质反应信息

文献信息

  • [EN] PIKFYVE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE PIKFYVE
    申请人:ACURASTEM INCORPORATED
    公开号:WO2021163727A1
    公开(公告)日:2021-08-19
    The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.
    本发明涉及作为磷脂酰肌醇-3-磷酸5-激酶(PIKfyve)抑制剂的化合物,以及它们用于治疗与PIKfyve相关的疾病和紊乱的用途。
  • Substituted Imidazopyridines as HDM2 Inhibitors
    申请人:Merck Sharp & Dohme Corp.
    公开号:US20140179680A1
    公开(公告)日:2014-06-26
    The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
    本发明提供了如本文所述的取代咪唑吡啶或其药用可接受的盐或溶剂。代表性化合物可用作HDM2蛋白的抑制剂。还公开了包括上述化合物的药物组合物以及使用它们治疗癌症的潜在方法。
  • SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS
    申请人:Su Wei-Guo
    公开号:US20140121200A1
    公开(公告)日:2014-05-01
    Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R 1 , R 2 , R 3 , R 4 and m are as defined in the specification.
    提供了式(1)的吡啶吡嗪化合物,以及其药物组合物和使用方法,其中R1、R2、R3、R4和m如规范中所定义。
  • [EN] 6-PHENYL-1H-IMIDAZO[4,5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN INHIBITORS<br/>[FR] DÉRIVÉS DE 6-PHÉNYL-1H-IMIDAZO[4,5-C]PYRIDINE-4-CARBONITRILE COMME INHIBITEUR DE LA CATHEPSINE
    申请人:ORGANON NV
    公开号:WO2009010491A1
    公开(公告)日:2009-01-22
    The present invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives having the general Formula (I), to pharmaceutical compositions comprising the same as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S related diseases such asatherosclerosis,obesity, inflammation and immune disorders, such as rheumatoid arthritis, psoriasis, cancer,and chronic pain, such as neuropathic pain.
    本发明涉及具有通式(I)的6-苯基-1H-咪唑[4,5-c]吡啶-4-碳腈衍生物,以及包含相同的药物组合物,以及利用这些衍生物制备用于治疗与S蛋白酶相关疾病的药物,如动脉粥样硬化、肥胖、炎症和免疫紊乱,如类风湿性关节炎、牛皮癣、癌症和慢性疼痛,如神经病性疼痛。
  • [EN] BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES<br/>[FR] INHIBITEURS DE KINASES À BASE DE CARBOXAMIDES BICYCLIQUES
    申请人:ABBOTT LAB
    公开号:WO2012097684A1
    公开(公告)日:2012-07-26
    Compounds of formula (I) or pharmaceutical acceptable salts are provided, wherein X1~X5, R1~R3, A, B, Z and n are defined in the description. And compositions containing said compounds, and the uses for inhibitors of kinases such as ALK, and the uses for treating cancer thereof are provided.
    提供了式(I)的化合物或药用可接受的盐,其中X1~X5,R1~R3,A,B,Z和n在描述中有定义。还提供了含有这些化合物的组合物,以及用于抑制激酶如ALK的用途,以及用于治疗癌症的用途。
查看更多